gm-csf vaccine
Biologicalexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT00524277)
Timeline
Indications
Mechanism of action
- Granulocyte-macrophage colony-stimulating factorImmunity, active
CSF2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gm-csf vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03376477 | Phase 2 | Jul 10, 2018 | Aduro BioTech, Celgene, Johns Hopkins University |
| NCT03014076 | Phase 1 | Jan 1, 2008 | Cancer Insight, LLC |
| NCT00524277 | Phase 2 | Jan 1, 2007 | Generex Biotechnology Corp., Norwell, Inc., United States Army, University of Texas at Houston |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aduro BioTech | For profit | 1 | 0 | 1 | 2018 |
| Cancer Insight, LLC | For profit | 1 | 1 | 1 | 2008 |
| Celgene | For profit | 1 | 0 | 1 | 2018 |
| Generex Biotechnology Corp. | For profit | 1 | 0 | 1 | 2007 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Norwell, Inc. | For profit | 1 | 0 | 1 | 2007 |
| United States Army | Government | 1 | 1 | 1 | 2007 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2007 |
8 organizations
Page 1 / 1